Bleeding Disorders Treatment Market - Global Industry Insights, Trends, Size, Share, Outlook, and Opportunity Analysis, 2018-2026
Seattle, WA -- (SBWIRE) -- 11/14/2019 -- Bleeding disorders are a group of disorders that result when the blood cannot clot properly. This means, in normal clotting, platelets stick together and form plug at the site of an injured blood vessels. Proteins in the blood vessels known as clotting factors interact to form a fibrin clot that holds platelets in one place and accelerates healing to occur at the site of injury along with preventing blood to escape from vessels. Occasionally, certain situations prevent blood from clotting properly, which can result in heavy or prolonged bleeding. Bleeding disorders can cause abnormal bleeding both outside and inside of the body. While some disorders can increase the blood loss drastically, other can cause bleeding to follow under the skin or in vigorous organs such as brain. Moreover, severe complications can arise when certain factors in the body are either missing or in low amount. Some bleeding disorders are present at the time of birth, while some are passed through generations.
Get PDF Brochure for Research Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/527
According to American Society of Hematology, in 2016, around 20,000 people in the U.S. suffered from hemophilia, a condition that is predominantly observed in males. Hemophilia is the most well-known inherited bleeding disorder, although it is rather rare. On the contrary, many people are affected by von Willebrand disease, the most common inherited bleeding disorder in the U.S. caused by clotting proteins. This disease can affect both males and females and is found in nearly 1% of the U.S. population. According to the Centers for Disease Control and Prevention (CDC) statistics, in the U.S. around 400 newborns suffer from hemophilia every year.
Global Bleeding Disorders Treatment Market
On the basis of type of disorder, the global bleeding disorders treatment market is classified into:
- Hemophilia A
- Hemophilia B
- von Willebrand Disease (vWD)
On the basis of drug class, the global bleeding disorders treatment market is classified into:
- Plasma Derived Coagulation Factor Concentrates
- Recombinant Coagulation Factor Concentrate
- Fibrin sealants
Generic products to drive growth of global bleeding disorders treatment market
Large customer pool, growing awareness regarding bleeding disorders, available treatment options, and favorable compensation policies are expected to drive growth of the global bleeding disorders treatment market during the forecast period. Moreover, a lot patents of existing brands are expiring, presenting lucrative opportunities for generic drug manufacturers to enter into the market. Global bleeding disorders market is mostly focused towards western countries of North America and Europe, owing to the high price of branded drugs. Low cost drugs will help in market penetration in emerging economies, where patients cannot afford high cost of medical treatment. Hence, availability of cheap generic drugs is expected to fuel growth in the countries of Middle East and Africa, Asia Pacific (APAC), and Latin America.
Request For Customization at: https://www.coherentmarketinsights.com/insight/request-customization/527
Among regions, North America is expected to account for the largest share in the global bleeding disorders treatment market over the forecast period. Moreover, Asia Pacific is expected to exhibit the highest growth during the forecast period, owing to growing awareness regarding these disorders in emerging economies such as China and India.
Key players in the market are involved in various growth strategies such as product launching, in order to expand their product portfolio and gain competitive edge in the market. For instance, in 2016, Shire introduced Vonvendi in the U.S., bringing the first recombinant von Willebrand factor treatment to market eight months after winning approval from the U.S. Food and Drug Administration (FDA).
Key players operating in the global bleeding disorders treatment market are Bayer Healthcare, Biogen Idec, Novo Nordisk, Xenetic Biosciences, Shire, Sanofi, Cangene Corporation, CSL Behring, Alnylam Pharmaceuticals, Pfizer, Inc., Novo Nordisk, Amgen, Inc., Janssen Pharmaceuticals, and Octapharma.
For More Details On this Report: https://www.coherentmarketinsights.com/ongoing-insight/bleeding-disorders-treatment-market-527